ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $787,091 | +2.2% | 29,001 | +15.7% | 0.00% | 0.0% |
| Q2 2023 | $770,402 | +85882.4% | 25,061 | +0.7% | 0.00% | -25.0% |
| Q1 2023 | $896 | -75.9% | 24,890 | -73.5% | 0.00% | -78.9% |
| Q4 2022 | $3,715 | -99.9% | 94,003 | -9.0% | 0.02% | -9.5% |
| Q3 2022 | $4,149,000 | -1.2% | 103,260 | +3.4% | 0.02% | -4.5% |
| Q2 2022 | $4,199,000 | +7.7% | 99,887 | -0.2% | 0.02% | +15.8% |
| Q1 2022 | $3,900,000 | -22.7% | 100,106 | -20.9% | 0.02% | -20.8% |
| Q4 2021 | $5,045,000 | +70.6% | 126,623 | +54.7% | 0.02% | +50.0% |
| Q3 2021 | $2,957,000 | +363.5% | 81,826 | +425.3% | 0.02% | +300.0% |
| Q2 2021 | $638,000 | +17.1% | 15,576 | +24.6% | 0.00% | 0.0% |
| Q1 2021 | $545,000 | -21.4% | 12,504 | -9.8% | 0.00% | -20.0% |
| Q4 2020 | $693,000 | +264.7% | 13,863 | +206.4% | 0.01% | +150.0% |
| Q3 2020 | $190,000 | +95.9% | 4,524 | +126.2% | 0.00% | +100.0% |
| Q2 2020 | $97,000 | – | 2,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |